HQL-975

HQL-975 is a phenyloxazole derivative developed as an orally active antidiabetic agent. It acts primarily as an insulin sensitizer and has demonstrated efficacy in preclinical models of type 2 diabetes (non-insulin-dependent diabetes mellitus). In animal studies, HQL‑975 administration led to reductions in plasma glucose, triglycerides, total cholesterol, non‑esterified fatty acids, and insulin levels. The drug enhances hepatic glucose utilization and decreases hepatic glucose production by increasing activities of enzymes such as hexokinase and fatty acid synthetase while decreasing activities of gluconeogenic enzymes like glucose‑6‑phosphatase and phosphoenolpyruvate carboxykinase. Additionally, it improves peripheral insulin action by enhancing insulin-stimulated glucose uptake in muscle and adipose tissue. These effects suggest that the hypoglycemic action of HQL‑975 is mediated through both hepatic metabolic modulation and improved peripheral tissue sensitivity to insulin[1][3][5][6].

Other names

3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-2S-propylamino-propionic acidO-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-N-propyl-L-tyrosineCAS 185679-16-7CAS185679-16-7CAS-185679-16-7